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Objective: In the Netherlands, the majority of hereditary head and neck paragan-
gliomas (HNPGL) are caused by germline variants in the succinate dehydrogenase
genes (SDHD, SDHB, SDHAF2). Here, we evaluate a four-generation family linked
to a novel SDHB gene variant with the manifestation of a HNPGL.
Design: A family-based study.
Setting: The VU University Medical Center (VUmc) Amsterdam, a tertiary clinic for
Otolaryngology and Head and Neck Surgery.
Participants and main outcome measures: The index patients presented with an
embryonic rhabdomyosarcoma and a non-Hodgkin lymphoma. Array-based compara-
tive genomic hybridisation (aCGH) analysis and multiplex ligation-dependent probe
amplification (MLPA) revealed a novel deletion of exon 1-3 in the SDHB gene, sus-
pected to predispose to paraganglioma (PGL)/pheochromocytoma (PHEO) syndrome
type 4. Subsequently, genetic counselling and DNA testing were offered to all family
members at risk. Individuals that tested positive for this novel SDHB gene variant
were counselled and additional clinical evaluation was offered for the identification
of HNPGL and/or PHEO.
Results: The DNA of 18 family members was tested, resulting in the identification
of 10 carriers of the exon 1-3 deletion in the SDHB gene. One carrier was diag-
nosed with a carotid body PGL and serum catecholamine excess, which was surgi-
cally excised. Negative SDHB immunostaining of the carotid body tumour confirmed
that it was caused by the SDHB variant. The remaining 9 carriers showed no evi-
dence of PGL/PHEO.
Conclusion: Deletion of exon 1-3 in the SDHB gene is a novel germline variant
associated with the formation of hereditary HNPGL.
1 | INTRODUCTION
Paragangliomas (PGLs) are rare, highly vascularised, usually benign
neoplasms of paraganglia, neuroendocrine organs derived from
neural crest chromaffin cells. PGLs can be found throughout the
body in association with the parasympathetic or sympathetic ner-
vous system. PGLs of the head and neck region are associated
with the parasympathetic nervous system. They secrete
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catecholamines in 4%-30% of the cases, which may cause ele-
vated blood pressure, palpitations, flushes and agitation, and may
ultimately result in severe cardiovascular complications.1-3 Head
and neck paragangliomas (HNPGLs) are most commonly found at
the carotid bifurcation (60%), but can also arise at the jugular
bulb, along the vagal nerve or the tympanic nerve.4 The closely
related pheochromocytoma (PHEO), also known as adrenal PGL,
together with the thoracic and abdominal extra-adrenal PGL are
paraganglion tumours associated with the sympathetic nervous
system.
In about 40% of the patients with an apparently sporadic presen-
tation of PGL or PHEO, a genetic predisposition can be identified.4
There is considerable genetic heterogeneity in PGL and PHEO, cur-
rently over 30 different genes have been associated with PGL/PHEO
formation. The majority of HNPGL, extra-adrenal PGL and PHEO are
caused by germline variants in genes encoding subunits and cofac-
tors of the succinate dehydrogenase (SDH) enzyme complex (A, B, C,
D, AF2).5-7 The associated syndromes are quite distinct. SDHB-linked
tumour syndrome is usually characterised by single tumours, and
gene variant carriers develop more frequently extra-adrenal PGLs,
PHEOs and metastatic disease than carriers in the other subunits of
the SDH gene.8 Furthermore, SDHB gene variants are implicated in
the development of renal cell carcinoma, papillary thyroid carcinoma
and GIST tumours.8-10
In this study, we describe the occurrence of HNPGL in a four-
generation family linked to a novel SDHB gene variant. The index
patients are 2 young sisters that did not present themselves with a
HNPGL or PHEO, but with a rhabdomyosarcoma and a non-Hodg-
kin lymphoma. Array-based comparative genomic hybridisation
(aCGH) analysis and subsequent multiplex ligation-dependent probe
amplification (MLPA) revealed a deletion of exon 1-3 in the SDHB
gene in both patients that has not been described previously.
Although SDHB immunostaining of the rhabdomyosarcoma and
non-Hodgkin lymphoma showed that there was no causal relation-
ship between the SDHB gene variant and these tumours, this novel
exon deletion was suspected to predispose to PGL/PHEO syn-
drome type 4 based on the characteristics of the gene variant
itself. Subsequently, genetic counselling and DNA testing were
offered to all family members. Clinical evaluation of the germline
variant carriers revealed an asymptomatic carotid body PGL in an
aunt of the index patients.
2 | MATERIALS AND METHODS
All the participating family members gave written informed consent
for the clinical study and DNA test. In case of individuals under
18 years of age, written informed consent was obtained from their
parents.
Data were collected from the VU University Medical Center
(VUmc), Amsterdam, the Netherlands, a tertiary referral centre for
HNPGL and/or PHEO in the Netherlands. Family members at risk
were offered genetic counselling and pre-symptomatic screening as
part of the protocol for standard care of pathogenic SDHB variant
carriers at risk in the Netherlands.11 SDHB gene variant analysis was
performed by the Leiden Genome Technology Center (LGTC) of the
Leiden University Medical Center (LUMC, Leiden, the Netherlands),
using Sanger sequencing on an ABI 377 (Applied Biosystems, Carls-
bad, CA) Genetic Analyzer and multiplex ligation-dependent probe
amplification (MLPA), P266 MLPA-kit (MRC Holland, Amsterdam, the
Netherlands).
Germline variant carriers were offered annual clinical surveillance
for PGL and PHEO at the departments of Otolaryngology/Head and
Neck Surgery and Endocrinology/Metabolic diseases of the VUmc.
Annual biochemical screening for excessive catecholamine excretion
included the measurement of (nor)adrenaline, vanillylmandelic acid
(VMA), dopamine, (nor)metanephrine and/or 3-methoxythyramine (3-
MT) in two 24-hour urinary samples, and/or plasma-free (nor)meta-
nephrine and/or 3-methoxythyramine (3-MT). All carriers were
offered magnetic resonance imaging (MRI) of the thorax/abdomen/
pelvis once every 2 years and head and neck region once every
3 years. Upon detection of a HNPGL (a carotid body tumour) and
catecholamine excess in one carrier, a multidisciplinary team consist-
ing of otolaryngologists, endocrinologists, geneticists, radiotherapists
and vascular surgeons advised surgical resection of the PGL. The
surgery was performed at the VUmc, Amsterdam, the Netherlands.
SDHB immunostaining was performed on tumour tissue according to
the protocol described elsewhere.12
3 | RESULTS
The index patients, 2 sisters (13 and 16 years old), were referred to
the Department of Clinical Genetics of the VU University Medical
Center for etiologic evaluation because of a medical history of a
embryonic rhabdomyosarcoma and a non-Hodgkin lymphoma,
respectively. Array-based comparative genomic hybridisation (aCGH)
and multiplex ligation-dependent probe amplification (MLPA) in both
sisters revealed a 16p12.2 microdeletion, a 20q12 deletion, and a
novel exon 1-3 deletion in the SDHB gene.
Based on positive SDHB immunostaining of the two index
tumours, no causal relationship could be established between the
SDHB gene variant and the occurrence of these tumours. Even so,
on grounds of the characteristics of the SDHB gene variant alone, it
was suspected that this variant could be pathogenic. Both a deletion
Key Points
• A deletion of exon 1-3 in the SDHB gene is associated
with the formation of hereditary HNPGL.
• Cascade screening of family members carrying this muta-
tion is important to detect pre-symptomatic PGL. Espe-
cially in case of catecholamine-producing tumours, timely
intervention may prevent cardiovascular complications.
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in SDHB exon 1 and in exon 3 are known to cause hereditary PGL
syndrome type 4 and predispose to HNPGL, PHEO, extra-adrenal
PGL and malignant PGL/PHEO.13-15 Despite the lack of apparent
symptomatic neuroendocrine tumours in this family, cascade screen-
ing was offered to the family members of these 2 patients.
Subsequently, 18 relatives at risk belonging to a four-generation
family with a total of 43 members were tested for this specific SDHB
exon deletion. Eight individuals tested negative and were considered
not to be at risk of PGL/PHEO formation. Ten family members (6
women, 4 men) were carriers of the deletion of exon 1-3 in the
SDHB gene (Figure 1).
The mean age at detection of the gene variant was 34 years
(range 11-57). The mean duration of follow-up was 26 months
(range 12.6-32.3). None of the germline variant carriers presented
with signs or symptoms suggestive of a PGL/PHEO during clinical
examination. However, a slight increase in plasma-free (nor)meta-
nephrine or 3-MT levels was observed in 5 variant carriers (50%) at
the time of diagnosis (Table 1). In one of these patients,
F IGURE 1 Pedigree of the SDHB-linked family. The asterisks show the index patients
TABLE 1 Phenotype of 10 relatives carrying the exon 1-3 deletion in SDHB
Sex Age at diagnosis PGL location Catecholamine biochemistry at diagnosis Additional mutation Other tumour (in history)
1 F 39 None Normal (serum) 16p12.2 del
2 M 29 None Normal (serum) None
3 M 23 None Elevated NM (serum) None
Elevated M (serum)
Elevated 3-MT (serum)
4 F 56 None Elevated NM (serum) None
Elevated M (serum)
Elevated 3-MT (serum)
5 F 53 None Elevated NM (serum) None
Normal M (serum)
Normal 3-MT (serum)
6 M 51 None Elevated NM (serum) None
Elevated M (serum)
Normal 3-MT (serum)
7 F 46 Carotid body PGLa Elevated NM (serum) None
Normal M (serum)
Normal 3-MT (serum)
8 F 16 None Normal (urine) None Non-Hodgkin Lymphomab
9 F 13 None Normal (urine) 16p12.2 del Embryonal rhabdomyosarcomab
20q12 del
10 M 10 None Normal (urine) 16p12.2 del
F, female; M, male; PGL, paraganglioma; NM, normetanephrine; 3-MT, 3-methoxythyramine;.
aSDHB-associated;
bnot-associated.
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pre- and post-contrast enhanced 3D time-of-flight (TOF) MR angiog-
raphy of the head and neck region revealed a mass at the right caro-
tid bifurcation, suggestive of a carotid body PGL (Figure 2).
Increased plasma-free normetanephrine levels were observed at
time of diagnosis and 24-hour ambulatory blood pressure monitoring
revealed blood pressure peaks. MR imaging of the thorax, abdomen
and pelvis showed no other localisation of a PGL or PHEO. Addi-
tional iodine-123-meta-iodobenzylguanidine (MIBG) scintigraphy did
not unequivocally identify the source of the catecholamine overpro-
duction. A multidisciplinary team consisting of otolaryngologist,
endocrinologists, radiotherapists and vascular surgeons advised surgi-
cal resection on grounds of the causative SDHB gene variant and
catecholamine excess. An alpha blockade protocol until the day of
surgery was followed, because of increased preoperative plasma
levels of catecholamine and observed peaks in blood pressure. The
carotid body PGL was removed in total via a transcervical approach
in an uncomplicated procedure (Figure 3). Histologic evaluation con-
firmed the diagnosis HNPGL, and negative SDHB immunostaining
indicated the causal relation between the SDHB exon 1-3 deletion
and the carotid body PGL. Biochemical evaluation 4 months after
surgery showed normalisation of plasma-free normetanephrine
levels.
4 | DISCUSSION
4.1 | Synopsis of new findings
In this report, we describe a novel deletion of exon 1-3 in SDHB
causing HNPGL formation. We tested 18 relatives belonging to a
four-generation family consisting of 43 members, of whom 10 were
identified to carry this novel SDHB germline variant. One patient
was diagnosed with an asymptomatic carotid body PGL and serum
catecholamine excess. Negative SDHB immunostaining of the tumour
tissue confirms the association between this novel SDHB variant and
the carotid body PGL.4
4.2 | Comparisons with other studies
Interestingly, the two paediatric index patients were diagnosed with a
non-Hodgkin lymphoma and an embryonal rhabdomyosarcoma. It is
now known that SDHx germline variants do not only predispose to
PGL/PHEO, but also to non-paraganglionic tumours such as gastroin-
testinal stromal tumours, renal cell carcinomas and pituitary adeno-
mas.8-10 The complete spectrum of the SDHB-linked phenotype has,
however, not yet been fully elucidated, because the SDHx genes are
not routinely evaluated in individuals with non-endocrine tumours. A
recent study has highlighted a possible role for SDHx gene variants in
lymphoid malignancies. One SDHB variant carrier has been described
with a Hodgkin lymphoma and an abdominal extra-adrenal PGL, and
one SDHC variant carrier with Hodgkin lymphoma and a positive fam-
ily history of PHEO/GIST.16 However, both the Hodgkin lymphoma
and normal lymphoid tissues of the SDHB variant carrier displayed
minimal SDHB staining, precluding definitive assessment of SDHB pro-
tein loss. Based on positive SDHB immunostaining of rhabdomyosar-
coma and lymphoma tissue in our index patients, a causal relationship
between the deletion of exon 1-3 in SDHB and the occurrence of
these tumours could not be established.
Only 1 patient was affected with an apparently asymptomatic
carotid body PGL, detected at the age of 47. The risk of developing
a PGL or PHEO (or penetrance) in SDHB germline variant carriers is
subject of recent debate. Initially, it was estimated to range between
50% and 70% at 50 years of age.7,9,17 These estimates are probably
F IGURE 2 Axial magnetic resonance imaging (MRI) of the head
and neck region showing a Shamblin type II carotid body
paraganglioma. 3D TOF (time-of-flight angiography) sequence is
used to visualise flow within vessels, without the need to administer
contrast intravenously
F IGURE 3 Surgical resection, via a transcervical approach, of the
paraganglioma located between the right internal and external
carotid arteries, and its close relationship with the hypoglossal nerve.
I, common carotid artery; II, external carotid artery; III, internal
carotid artery; IV, paraganglioma; V, hypoglossal nerve
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inflated, as recent studies using more thorough pedigree analysis and
a more robust statistical correction for the ascertainment bias show
a lower age-dependent penetrance of SDHB variants, approximately
9%-21% at 50 years. These reports also indicate that there are no
significant differences in the penetrance of different types of SDHB
variants. The low penetrance of the SDHB variant found in this fam-
ily is in line with these recent reports.18-20
4.3 | Clinical applicability of the study
The management of HNPGL is challenging and requires a tailor-made
approach. The management strategy is based on several important fac-
tors, such as patient characteristics (ie age, comorbidities and patient
preferences) and tumour characteristics (ie localisation, size, growth
rate, biochemical activity and multicentricity). The causal gene variant
plays an increasingly prominent role in the clinical decision-making, as
different genes confer different risks and are associated with different
clinical phenotypes. SDHB variants causing PGL syndrome type 4 are
usually associated with single PGL/PHEO that have a higher risk of
progression to metastatic disease than PGL/PHEO associated with
other SDH genes.7,17 This study identifies a novel deletion of exon 1-3
in SDHB causing HNPGL. Cascade testing of family members at risk
identified a patient with a pre-symptomatic carotid body tumour, ele-
vated catecholamine levels and high blood pressure, which normalised
after surgical resection of the tumour.
5 | CONCLUSION
In this report, we present a novel deletion of exon 1-3 in the SDHB
gene associated with the formation of hereditary HNPGL. The pene-
trance of this gene variant seems low. Cascade screening of family
members carrying this mutation is important to detect pre-sympto-
matic PGL. Especially in case of catecholamine-producing tumours,
timely intervention may prevent cardiovascular complications.
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